{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:40:51Z","timestamp":1777977651489,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s10067-010-1577-1","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T03:31:21Z","timestamp":1285817481000},"page":"133-137","source":"Crossref","is-referenced-by-count":21,"title":["Tumor necrosis factor-alpha (TNF-\u03b1)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature"],"prefix":"10.1007","volume":"30","author":[{"given":"Raquel","family":"Cuchacovich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Richert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis R.","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,1]]},"reference":[{"key":"1577_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0899-7071(94)00022-5","volume":"19","author":"J Farman","year":"1995","unstructured":"Farman J, Ramirez G, Brunetti J, Tuvia J, Ng C, Rotterham H (1995) Abdominal manifestations of sarcoidosis, CT appearances. Clin Imaging 19:30\u201333","journal-title":"Clin Imaging"},{"key":"1577_CR2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0025-6196(11)63733-6","volume":"73","author":"KG Ishak","year":"1998","unstructured":"Ishak KG (1998) Sarcoidisis of the liver and bile duct. Mayo clinic proc 73:467\u2013472","journal-title":"Mayo clinic proc"},{"issue":"suppl 1","key":"1577_CR3","first-page":"40","volume":"30","author":"JH Lefkowitch","year":"1999","unstructured":"Lefkowitch JH (1999) Hepatic granulomas. J Hepatol 30(suppl 1):40\u201345","journal-title":"J Hepatol"},{"key":"1577_CR4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4065\/76.1.84","volume":"76","author":"VV Menghini","year":"2001","unstructured":"Menghini VV, Arora AS (2001) Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 76:84\u201386","journal-title":"Mayo Clin Proc"},{"key":"1577_CR5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","volume":"26","author":"GJ Tobon","year":"2007","unstructured":"Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM (2007) Serious liver disease induced by infliximab. Clin Rheumatol 26:578\u2013581","journal-title":"Clin Rheumatol"},{"key":"1577_CR6","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/ajrccm.156.5.97-02050","volume":"156","author":"MW Ziegenhagen","year":"1997","unstructured":"Ziegenhagen MW, Benner UK, Zissel G (1997) Sarcoidosis TNF-alpha release from alveolar macrophages and serum level of IL-2R are prognostic markers. Am J Respir Crit Care Med 156:1586\u20131598","journal-title":"Am J Respir Crit Care Med"},{"key":"1577_CR7","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/art.21468","volume":"53","author":"NJ Sweiss","year":"2005","unstructured":"Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH (2005) Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 53:788\u2013791","journal-title":"Arthritis Rheum"},{"key":"1577_CR8","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","volume":"127","author":"JD Doty","year":"2005","unstructured":"Doty JD, Mazur JE, Judson MA (2005) Treatent of sarcoidosis with infliximab. Chest 127:1064\u20131071","journal-title":"Chest"},{"key":"1577_CR9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2002.004226","volume":"63","author":"C Pritchard","year":"2004","unstructured":"Pritchard C, Nadarajah K (2004) Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 63:318\u2013320","journal-title":"Ann Rheum Dis"},{"key":"1577_CR10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0012-3692(15)50471-6","volume":"128","author":"RP Baughman","year":"2005","unstructured":"Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A (2005) Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 128:1047\u20131062","journal-title":"Chest"},{"key":"1577_CR11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","volume":"24","author":"JP Utz","year":"2003","unstructured":"Utz JP, Limper AH, Kalra S et al (2003) Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 24:177\u2013185","journal-title":"Chest"},{"key":"1577_CR12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1164\/rccm.200603-402OC","volume":"174","author":"RP Baughman","year":"2006","unstructured":"Baughman RP, Drent M, Kavuru M et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174:732\u2013733","journal-title":"Am J Respir Crit Care Med"},{"key":"1577_CR13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.21336","volume":"53","author":"K Phillips","year":"2005","unstructured":"Phillips K, Weinblatt M (2005) Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum 53:618\u2013620","journal-title":"Arthritis Rheum"},{"key":"1577_CR14","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/art.22351","volume":"55","author":"FD O\u2019Shea","year":"2006","unstructured":"O\u2019Shea FD, Marras TK, Inman RD (2006) Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Care Res 55:978\u2013981","journal-title":"Arthritis Care Res"},{"key":"1577_CR15","first-page":"99","volume":"25","author":"R Almodovar","year":"2007","unstructured":"Almodovar R, Izquierdo M, Zarco P, Javier Quiros F, Mazzucchelli R, Steen B (2007) Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 25:99\u2013101","journal-title":"Clin Exp Rheumatol"},{"key":"1577_CR16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2006.01949.x","volume":"21","author":"C Bachmeyer","year":"2007","unstructured":"Bachmeyer C, Blum L, Petitjean B, Kemiche F, Pertuiset E (2007) Granulomatous tattoo reaction in a patient treated with etanercept. J Eur Acad Dermatol Venereol 21:550\u2013552","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1577_CR17","first-page":"645","volume":"21","author":"PJ Hashkes","year":"2003","unstructured":"Hashkes PJ, Shajrawi I (2003) Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 21:645\u2013646","journal-title":"Clin Exp Rheumatol"},{"key":"1577_CR18","first-page":"2313","volume":"34","author":"G Sturfelt","year":"2007","unstructured":"Sturfelt G, Christensson B, Bynke G, Saxne T (2007) Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J Rheumatol 34:2313\u20132314","journal-title":"J Rheumatol"},{"key":"1577_CR19","first-page":"648","volume":"34","author":"A Kudrin","year":"2007","unstructured":"Kudrin A, Chilvers ER, Ginawi A et al (2007) Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol 34:648\u2013649","journal-title":"J Rheumatol"},{"key":"1577_CR20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/rheumatology\/kep046","volume":"48","author":"CI Da\u012ben","year":"2009","unstructured":"Da\u012ben CI, Monnier A, Claudepierre P et al (2009) Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology 48:883\u2013886","journal-title":"Rheumatology"},{"key":"1577_CR21","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1592\/phco.27.10.1446","volume":"27","author":"RE Farah","year":"2007","unstructured":"Farah RE, Shai MD (2007) Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy 27:1446\u20131448","journal-title":"Pharmacotherapy"},{"key":"1577_CR22","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s10067-007-0594-1","volume":"26","author":"K Verschueren","year":"2007","unstructured":"Verschueren K, Van E, Verschueren P (2007) Development of sarcoidosis in etanercept treated rheumatoid arthritis patients. Clin Rheumatol 26:1969\u20131971","journal-title":"Clin Rheumatol"},{"key":"1577_CR23","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2169\/internalmedicine.47.0602","volume":"47","author":"T Ishiguro","year":"2008","unstructured":"Ishiguro T, Takayanagi N, Kurashima K (2008) Development of sarcoidosis during etanercept therapy. Intern Med 47:1021\u20131025","journal-title":"Intern Med"},{"key":"1577_CR24","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.3899\/jrheum.090030","volume":"36","author":"E Toussirot","year":"2009","unstructured":"Toussirot E, Berthelot JM, Pertuiset E (2009) Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha blocking agent: a case series. J Rheumatol 36:2421\u20132427","journal-title":"J Rheumatol"},{"key":"1577_CR25","first-page":"471","volume":"26","author":"E Toussirot","year":"2008","unstructured":"Toussirot E, Pertuiset E, Kantelip B (2008) Sarcoidosis occurring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clic Exp Rheumatol 26:471\u2013475","journal-title":"Clic Exp Rheumatol"},{"key":"1577_CR26","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3899\/jrheum.080383","volume":"35","author":"VM Ognenovski","year":"2008","unstructured":"Ognenovski VM, Ojo TC, Fox DA et al (2008) Etanercept-associated pulmonary granulomatous inflammation in patients with rheumatoid arthritis. J Rheumatol 35:2279\u20132282","journal-title":"J Rheumatol"},{"issue":"11","key":"1577_CR27","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jcp.56.11.850","volume":"56","author":"DR Gaya","year":"2003","unstructured":"Gaya DR, Thorburn D, Oien KA, Morris AJ, Stanley AJ (2003) Hepatic granulomas: a 10\u00a0year single centre experience. J Clin Pathol 56(11):850\u2013853","journal-title":"J Clin Pathol"},{"issue":"5","key":"1577_CR28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00004836-200405000-00011","volume":"38","author":"R \u00d6zaras","year":"2004","unstructured":"\u00d6zaras R, Tahan V, Mert A et al (2004) The prevalence of hepatic granulomas in chronic hepatitis C. J Clin Gastroenterol 38(5):449\u2013452","journal-title":"J Clin Gastroenterol"},{"issue":"11","key":"1577_CR29","first-page":"2286","volume":"35","author":"M Farah","year":"2008","unstructured":"Farah M, Al Rashidi A, Owen DA, Yoshida EM, Reid GD (2008) Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 35(11):2286\u20132287","journal-title":"J Rheumatol"},{"key":"1577_CR30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1214\/aoms\/1177729885","volume":"21","author":"FE Grubbs","year":"1950","unstructured":"Grubbs FE (1950) Sample criteria for testing outlying observations. Ann Math Stat 21:27\u201358","journal-title":"Ann Math Stat"},{"key":"1577_CR31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF01891203","volume":"2","author":"JP Royston","year":"1992","unstructured":"Royston JP (1992) Approximating the Shapiro\u2013Wilk W test for non-normality. Stat Comput 2:117\u2013119","journal-title":"Stat Comput"},{"issue":"7","key":"1577_CR32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrrheum.2009.105","volume":"5","author":"KL Winthrop","year":"2009","unstructured":"Winthrop KL, Chiller T (2009) Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 5(7):405\u2013410","journal-title":"Nat Rev Rheumatol"},{"key":"1577_CR33","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","volume":"64","author":"J Askling","year":"2005","unstructured":"Askling J, Fored CM, Brandt L, Baecklund E et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:1421\u20131426","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1577_CR34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","volume":"37","author":"MF Costa","year":"2008","unstructured":"Costa MF, Said NR, Zimmermann B (2008) Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37(6):381\u2013387","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"1577_CR35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11926-008-0072-z","volume":"10","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Cuadrado MJ, Khamashta MA (2008) Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep 10(6):442\u2013448","journal-title":"Curr Rheumatol Rep"},{"key":"1577_CR36","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/RHU.0b013e318190dd88","volume":"14","author":"R Cuchacovich","year":"2008","unstructured":"Cuchacovich R, Espinoza G, Virk Z, Espinoza LR (2008) Biologic therapy (TNF-\u03b1 Antagonists) induced psoriasis, a cytokine imbalance between TNF-\u03b1 and IFN? J Clin Rheumatol 14:353\u2013356","journal-title":"J Clin Rheumatol"},{"issue":"9","key":"1577_CR37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2036.2009.03955.x","volume":"29","author":"G Fiorino","year":"2009","unstructured":"Fiorino G, Allez M, Malesi A, Danese S (2009) anti TNF induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 29(9):921\u2013927","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1577_CR38","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","volume":"22","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22(5):847\u2013861","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1577_CR39","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003495-200565050-00006","volume":"65","author":"MT Nurmohamed","year":"2005","unstructured":"Nurmohamed MT, Dijkmans BA (2005) Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 65:661\u2013694","journal-title":"Drugs"},{"key":"1577_CR40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.semarthrit.2005.01.003","volume":"34","author":"B Haraoui","year":"2005","unstructured":"Haraoui B (2005) Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 34:7\u201311","journal-title":"Semin Arthritis Rheum"},{"issue":"61","key":"1577_CR41","first-page":"478","volume":"28","author":"B Kolarz","year":"2007","unstructured":"Kolarz B, Targo\u0144ska-Stepniak B, Darmochwa\u0142-Kolarz D, Majdan M (2007) Autoimmune aspects of treatment with TNF-alpha inhibitors. Postepy Hig Med Dosw 28(61):478\u2013484","journal-title":"Postepy Hig Med Dosw"},{"key":"1577_CR42","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","volume":"151","author":"KM Mohler","year":"1993","unstructured":"Mohler KM, Torrance DS, Smith CA et al (1993) Soluble Tumor Necrosis Factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548\u20131561","journal-title":"J Immunol"},{"key":"1577_CR43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1084\/jem.175.2.323","volume":"175","author":"D Aderka","year":"1992","unstructured":"Aderka D, Engelmann H, Maor Y et al (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323\u2013329","journal-title":"J Exp Med"},{"key":"1577_CR44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1378\/chest.127.1.251","volume":"127","author":"H Dai","year":"2005","unstructured":"Dai H, Guzman J, Chen B et al (2005) Production of soluble tumor necrosis factor receptors and tumor necrosis factor-\u03b1 by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest 127:251\u2013256","journal-title":"Chest"},{"key":"1577_CR45","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/infdis\/167.6.1344","volume":"167","author":"L Shapiro","year":"1993","unstructured":"Shapiro L, Clark BD, Orencole SF et al (1993) Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic human. J Infect Dis 167:1344\u20131350","journal-title":"J Infect Dis"},{"key":"1577_CR46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2796.1993.tb00659.x","volume":"233","author":"I Olsson","year":"1993","unstructured":"Olsson I (1993) The cytokine network. J Int Med 233:103\u2013105","journal-title":"J Int Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1577-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-010-1577-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1577-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:06:04Z","timestamp":1740542764000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-010-1577-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1007\/s10067-010-1577-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,1]]}}}